scispace - formally typeset
M

Mark J. Tomishima

Researcher at Memorial Sloan Kettering Cancer Center

Publications -  47
Citations -  7941

Mark J. Tomishima is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Embryonic stem cell & Induced pluripotent stem cell. The author has an hindex of 25, co-authored 46 publications receiving 6916 citations. Previous affiliations of Mark J. Tomishima include Kettering University.

Papers
More filters
Journal ArticleDOI

Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling

TL;DR: Noggin/SB431542-based neural induction should facilitate the use of hES and hiPS cells in regenerative medicine and disease modeling and obviate the need for protocols based on stromal feeders or embryoid bodies.
Journal ArticleDOI

Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs

TL;DR: The derivation of patient-specific FD-iPSCs and the directed differentiation into cells of all three germ layers including peripheral neurons are reported, illustrating the promise of iPSC technology for gaining new insights into human disease pathogenesis and treatment.
Journal ArticleDOI

Stoichiometric and temporal requirements of Oct4, Sox2, Klf4, and c-Myc expression for efficient human iPSC induction and differentiation

TL;DR: The vector system described here presents a powerful tool for mechanistic studies of reprogramming and the optimization of hiPSC generation as well as defining the optimal stoichiometry of RF expression to be highly sensitive to Oct4 dosage.
Journal ArticleDOI

Derivation of neural crest cells from human pluripotent stem cells

TL;DR: In this article, the authors provide protocols for the step-wise differentiation of human embryonic stem cells (hESCs) or human induced pluripotent stem cells(hiPSCs) into neuroectodermal and neural crest (NC) cells using either the MS5 coculture system or a novel defined culture method based on pharmacological inhibition of bone morphogenetic protein and transforming growth factor-beta signaling pathways.